AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.
View Top Employees from AVEO OncologyWebsite | http://www.aveooncology.com |
Ticker | AVEO |
Revenue | $28 million |
Funding | $502.3 million |
Employees | 192 (170 on RocketReach) |
Founded | 2001 |
Address | 30 Winter St 3rd Floor, Boston, Massachusetts 02108, US |
Phone | (857) 400-0101 |
Fax | (617) 995-4995 |
Technologies |
JavaScript,
HTML,
PHP
+59 more
(view full list)
|
Industry | Biotechnology Research, Pharmaceuticals, Biotechnology, Oncology, Healthcare, Science and Engineering, Health Care, Medical |
Web Rank | 3 Million |
Keywords | Oncology, Cancer Treatment, Targeted Cancer Therapies, Precision Medicine, Clinical Trials, Drug Development And Manufacturing, Research And Development, Biotechnology |
Competitors | Helix Biopharma Corp (HBPCF), Kronos Bio, Leap Therapeutics, TARIS Bio, TYME Technologies Inc. |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies |
Looking for a particular AVEO Oncology employee's phone or email?
The AVEO Oncology annual revenue was $28 million in 2024.
Jeb Ledell is the COO of AVEO Oncology.
170 people are employed at AVEO Oncology.
AVEO Oncology is based in Boston, Massachusetts.
The NAICS codes for AVEO Oncology are [3254, 325, 32541, 32].
The SIC codes for AVEO Oncology are [283, 28].